Last reviewed · How we verify

Immunic AG — Portfolio Competitive Intelligence Brief

Immunic AG pipeline: 0 marketed, 0 filed, 2 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Placebo matching IMU-838 tablets Placebo matching IMU-838 tablets phase 3 Selective immunomodulator Intracellular signaling (TYK2 and related kinases) Immunology
IMU-838 tablets IMU-838 tablets phase 3 DHODH inhibitor Dihydroorotate dehydrogenase (DHODH) Immunology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Medicines for Malaria Venture · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Immunic AG:

Cite this brief

Drug Landscape (2026). Immunic AG — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/immunic-ag. Accessed 2026-05-13.

Related